- Home
- DIN vs XERS Comparison
DIN vs XERS Comparison
Compare DIN & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIN
- XERS
- Stock Information
- Founded
- DIN 1958
- XERS 2005
- Country
- DIN United States
- XERS United States
- Employees
- DIN N/A
- XERS N/A
- Industry
- DIN Restaurants
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- DIN Consumer Discretionary
- XERS Health Care
- Exchange
- DIN Nasdaq
- XERS Nasdaq
- Market Cap
- DIN 468.5M
- XERS 526.3M
- IPO Year
- DIN 1991
- XERS 2018
- Fundamental
- Price
- DIN $23.32
- XERS $5.49
- Analyst Decision
- DIN Hold
- XERS Strong Buy
- Analyst Count
- DIN 8
- XERS 6
- Target Price
- DIN $29.50
- XERS $5.92
- AVG Volume (30 Days)
- DIN 691.0K
- XERS 4.3M
- Earning Date
- DIN 03-05-2025
- XERS 03-06-2025
- Dividend Yield
- DIN 8.77%
- XERS N/A
- EPS Growth
- DIN N/A
- XERS N/A
- EPS
- DIN 4.22
- XERS N/A
- Revenue
- DIN $812,306,000.00
- XERS $203,070,000.00
- Revenue This Year
- DIN $1.02
- XERS $31.75
- Revenue Next Year
- DIN $1.15
- XERS $21.09
- P/E Ratio
- DIN $5.51
- XERS N/A
- Revenue Growth
- DIN N/A
- XERS 23.89
- 52 Week Low
- DIN $22.36
- XERS $1.69
- 52 Week High
- DIN $47.19
- XERS $6.07
- Technical
- Relative Strength Index (RSI)
- DIN 38.26
- XERS 68.07
- Support Level
- DIN $23.84
- XERS $4.33
- Resistance Level
- DIN $25.10
- XERS $6.07
- Average True Range (ATR)
- DIN 1.06
- XERS 0.30
- MACD
- DIN -0.06
- XERS 0.01
- Stochastic Oscillator
- DIN 10.00
- XERS 66.67
About DIN Dine Brands Global Inc.
Dine Brands Global Inc owns and franchises thousands of restaurants under the Applebee's and International House of Pancakes names. Almost all company restaurants are located in the United States and franchised. Royalty revenue, which the company gets from franchisees based on franchisees' sales, accounts for roughly three-quarters of total company revenue. The company also earns revenue by leasing restaurant sites to franchisees. The company has four reportable segments Franchise operations, (an aggregation of Applebee's and IHOP franchise operations), Rental operations, Financing operations, and Company-operated restaurant operations. The majority of revenue is derived from the Franchise operations segment.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.